We Pioneered a Technology to Save Millions of Poor Children, But a Worldwide Smear Campaign Has Blocked It

We Pioneered a Technology to Save Millions of Poor Children, But a Worldwide Smear Campaign Has Blocked It

On left, a picture of white rice next to Golden Rice, and on right, a girl who lost one eye due to vitamin A deficiency.

(Photo Credit: Golden Rice Humanitarian Board)


Keep Reading Keep Reading
Adrian Dubock, Ingo Potrykus, Peter Beyer
Peter Beyer headed a research group at University of Freiburg, Germany, with a strong focus on improving the nutritional value of crop plants. Ingo Potrykus worked at ETH Zurich, Switzerland, with a research group using genetic engineering technology applied to "food security" crops in developing countries. Adrian Dubock designed the international collaboration, and its governance, for turning the results of the Potrykus and Beyer teams into a useful product – Golden Rice - to combat vitamin A deficiency, a long-standing objective which all three share. Potrykus is the Chair of the Golden Rice Humanitarian Board, Beyer and Dubock are Board members, and Dubock is also the Executive Secretary of the Board. In common with other Board members, all three are unpaid volunteers.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.